Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.
The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia. The system features a closed-loop control mechanism that precisely adjusts ultrasound energy delivery based on continuous feedback from MR temperature mapping, enabling controlled ablation of prostate tissue while preserving surrounding structures.
Founded in 2015, Profound Medical has secured regulatory approvals and clearances in multiple jurisdictions, including CE mark certification for the European market and FDA clearance in the United States. The company has established a network of clinical partners and distributors across North America and Europe, where its technology is being adopted in leading cancer centers and urology clinics.
Profound Medical’s leadership comprises professionals with extensive experience in medical device development, clinical operations and regulatory affairs. The company continues to invest in research and development to expand its ultrasound platform for additional therapeutic indications and to support ongoing clinical studies aimed at improving patient outcomes.
AI Generated. May Contain Errors.
Free PROF Stock Alerts